Последние добавленные видео:
Speaker:-Francesco-Passamonti
-
5 months ago
61 5 months ago 2:48Personalized transplant decision-making for patients with myelofibrosis
-
5 months ago
65 5 months ago 1:53Efficacy and safety of fedratinib in patients with myelofibrosis and low platelet counts
-
1 year ago
64 1 year ago 1:14Modern prognostication in MPNs: improving risk stratification & treatment approaches
-
3 years ago
225 3 years ago 1:22Real-world outcomes of patients with MF treated with fedratinib post-ruxolitinib discontinuation
-
1 year ago
78 1 year ago 1:19The current state-of-the-art in PV and future outlooks
-
5 months ago
70 5 months ago 1:22Managing patients with MPNs and co-existing inflammatory conditions or cardiovascular risks
-
16 hours ago
10476 16 hours ago 9:19Americana: Musk fonda il suo partito!
-
1 year ago
29 1 year ago 1:13Results from the ACE‐536‐MF‐001 study
-
3 years ago
342 3 years ago 3:23Novel drugs and treatment strategies for myelofibrosis
-
3 years ago
177 3 years ago 1:23RESPONSE-2 5-year follow-up update: ruxolitinib vs BAT in polycythemia vera without splenomegaly
-
5 months ago
99 5 months ago 2:24The latest advancements in disease-modifying therapies for myelofibrosis
-
3 years ago
254 3 years ago 2:12REFINE: Phase II study of navitoclax + ruxolitinib in JAK inhibitor-naive patients with MF
-
3 months ago
80 3 months ago 4:15Rescue strategies after failure of SCT in myelofibrosis
-
3 years ago
121 3 years ago 1:30Optimal approach to first-line therapy in myelofibrosis
-
3 years ago
2124 3 years ago 3:39The treatment of low and high-risk polycythemia vera
-
3 years ago
289 3 years ago 1:58JUMP: update on ruxolitinib for myelofibrosis